Literature DB >> 8683454

Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies?

S Dutta1, Y Matsumoto, W F Ebling.   

Abstract

Many drug concentration-effect relationships are described by the nonlinear sigmoid E(max) model. Clinical considerations frequently limit the magnitude of effect intensity that may be produced; the most pronounced effect intensity may be considerably below E(max). We have tested and quantified the influence of this limitation on the estimatability of the sigmoid E(max) model parameters. We have used the estimated parameter values to calculate data descriptors (drug concentrations required to produce certain effect intensities) and compared these with concentrations determined by using exact parameter values. We found that when the highest measured effect intensity was less than 95% of E(max), E(max) and EC50 were poorly estimated (high coefficient of variation and pronounced bias). Nevertheless, the fit to the data was quite good and the data descriptors were estimated with precision within the range for which data were available but not beyond. Baseline effect was estimated with good precision but the sigmoidicity parameter (gamma) was highly variable. Thus, where clinical considerations prevent determination of concentration-effect data near the maximum effect intensity, E(max) and EC50 estimations are unreliable. The use of estimable data descriptors is proposed to characterize the concentration-effect relationship under these conditions.

Mesh:

Year:  1996        PMID: 8683454     DOI: 10.1021/js950067y

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  13 in total

1.  Nonlinearity detection: advantages of nonlinear mixed-effects modeling.

Authors:  E N Jonsson; J R Wade; M O Karlsson
Journal:  AAPS PharmSci       Date:  2000

2.  Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models.

Authors:  Wojciech Krzyzanski; Jacek Dmochowski; Nobuko Matsushima; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-08-29       Impact factor: 2.745

3.  Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing.

Authors:  G J Singh; N Fleischer; L Lesko; R Williams
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

4.  Feasibility of effect-controlled clinical trials of drugs with pharmacodynamic hysteresis using sparse data.

Authors:  W F Ebling; Y Matsumoto; G Levy
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

5.  Effect-site concentrations of remifentanil causing bradycardia in hypnotic and non-hypnotic patients.

Authors:  Kazuko Hayashi; Akiko Tanaka
Journal:  J Clin Monit Comput       Date:  2015-10-13       Impact factor: 2.502

6.  Feasibility of Exposure-Response Analyses for Clinical Dose-Ranging Studies of Drug Combinations.

Authors:  Theodoros Papathanasiou; Anders Strathe; Andrew C Hooker; Trine Meldgaard Lund; Rune Viig Overgaard
Journal:  AAPS J       Date:  2018-04-23       Impact factor: 4.009

7.  Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition.

Authors:  Anshu Marathe; Scott Van Wart; Donald E Mager
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-17       Impact factor: 2.745

8.  Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure.

Authors:  L Brynne; J L McNay; H G Schaefer; K Swedberg; C G Wiltse; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

9.  Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children.

Authors:  B J Anderson; N H Holford; G A Woollard; P L Chan
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

10.  Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model.

Authors:  Boris Gorelik; Irit Ziv; Revital Shohat; Michael Wick; W David Hankins; David Sidransky; Zvia Agur
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.